Clinical Trial Update: Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

An ongoing Phase I study at MD Anderson tests allogeneic CD70 CAR NK cells engineered with TGF-beta receptor type 2 knockout for treatment-refractory clear cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells (TGFBR2 knockout CD70 CAR NK cells)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Clear Cell Carcinoma, Phase 1 | Phase 1 | Status: RECRUITING